PRODUCTION, ANALYSIS, AND DISTRIBUTION OF CANNABIS AND RELATED MATERIALS. POP: MARCH 23, 2015 - MARCH 22, 2020. N01DA-15-7793.

行使期权期间4(合同年5)；1 669 640美元。 行使期权数量2b(合同第4年)：311,759美元。 简而言之，目标是：(1)培育和收获、加工、分析、储存和分发 用于研究的大麻(大麻)；(2)提取大麻以生产纯净和标准化的(当前 良好制造规范(CGMP)级)大麻提取物含有不同浓度的 Delta-9-四氢大麻酚(THC)和大麻二酚(CBD)；(3)分离cGMP和研究级THC， CBD和其他大麻类物质；(4)定期分析大麻 提取物和分离的大麻素的真实性、纯度和稳定性；(5)开发新的方法 用于种植大麻植物，含有高THC，低CBD；高CBD，低THC；以及等强度 CBD和THC；(6)制造、分析、确定稳定性、储存和供应大麻香烟； (7)供应大麻、大麻提取物、其他大麻素和大麻香烟 研究调查人员和/或NIDA药物供应计划 授权。

To exercise Option Period 4 (Contract Year 5); $1,669,640. To exercise Option Quantity 2b (Contract Year 4): $311,759. In brief, the objectives are to: (1) cultivate and harvest, process, analyze, store, and distribute cannabis (marijuana) for research; (2) extract cannabis to produce pure and standardized (current Good Manufacturing Practices (cGMP)­ grade) cannabis extracts containing varying concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); (3) isolate cGMP and research grade THC, CBD, and other cannabinoids; (4) periodically analyze cannabis extracts, and isolated cannabinoids for authenticity, purity and stability; (5) develop new methods for growing cannabis plants containing high THC, low CBD; high CBD, low THC; and equal strength of CBD and THC; (6) manufacture, analyze, determine stability, store, and supply marijuana cigarettes; and (7) supply cannabis, cannabis extract, other cannabinoids, and marijuana cigarettes to research investigators and/or to the NIDA Drug Supply program upon NIDA authorization.